Autor: |
Monika Pajewska, Olga Partyka, Aleksandra Czerw, Andrzej Deptała, Elżbieta Cipora, Izabela Gąska, Marek Wojtaszek, Katarzyna Sygit, Marian Sygit, Edyta Krzych-Fałta, Daria Schneider-Matyka, Anna M. Cybulska, Elżbieta Grochans, Alicja Asendrych-Woźniak, Agnieszka Romanowicz, Jarosław Drobnik, Ewa Bandurska, Weronika Ciećko, Barbara Maciuszek-Bartkowska, Mateusz Curyło, Kacper Wróbel, Remigiusz Kozłowski, Michał Marczak |
Jazyk: |
angličtina |
Rok vydání: |
2023 |
Předmět: |
|
Zdroj: |
Cancers, Vol 15, Iss 17, p 4400 (2023) |
Druh dokumentu: |
article |
ISSN: |
2072-6694 |
DOI: |
10.3390/cancers15174400 |
Popis: |
Pancreatic cancer (PC) is usually diagnosed at an advanced stage of its development, which results in lower overall survival (OS). Prognosis is also poor even with curative-intent surgery. Approximately 80% of patients with localized PDAC have micrometastases at the time of diagnosis, which leads to a worse prognosis than in other cancers. The objective of this study is to present the progress in the treatment of metastatic pancreatic cancer based on the recommendations of oncological scientific societies, such as ESMO, NCCN, ASCO, NICE and SEOM, over the last 5 years. Combined FOLFIRINOX therapy is mostly a recommended therapy among patients with good performance statuses, while gemcitabine is recommended for more fragile patients as a first-line treatment. The newest guidelines suggest that molecular profiling of the tumor should be the first step in determining the course of treatment. The use of modern molecular therapies in patients with specific gene mutations should extend the survival of patients with this disease. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|